Zim Laboratories Ltd

- The company has completed the planned capex, with only a marginal increase of around INR 5 crore related to CAPA implementation. - Borrowings for the balance capex and CAPA have already been tied up; no further increase in borrowings or capex is planned. - Term loan repayment has already started, and no new debt is anticipated. - Working capital levels and debt gearing are stable, with no further debt increase expected. - There is no mention of any new equity fundraising plans in the provided text.

- The previously planned capex has been mostly completed. - There is a marginal additional capex of around INR 5 crore related to CAPA implementation. - Another INR 5 to 7 crore is planned for completion of balance capex, with borrowings already tied up. - No significant further increase in borrowing or capex is expected beyond these amounts. - The CAPA-related capex is approved by the Board. - No mention of strategic investments beyond remedial and capex activities shared.

- The company expects base business revenues in H2 FY '26 to be in line with last year's numbers, compensating for H1 shortfall. - NIP (New Innovative Products) and OTF (Orally Thin Films) sales are anticipated to return to approx. INR 15–16 crores run rate in Q3 and Q4 FY '26. - India and export order books remain strong, supporting revenue recovery in H2 FY '26 and beyond. - New Marketing Authorizations (MAs) recently received—especially in ROW markets—are expected to commercialize within 3 to 6 months, driving growth. - EU-GMP compliance and remediation expected by Q4 FY '26 will enable resumption of EU market sales starting Q1 or Q2 FY '27. - Management targets 20–25% revenue growth and improved margins (14–15% EBITDA) in FY '27, assuming timely EU sales restart. - Nutra segment demand expected to stabilize in Q3/Q4 FY '26 with institutional orders recovering. - Working capital and inventory levels will rise proportionate to turnover growth.

- The company expects to achieve last year's revenue numbers in H2 FY '26, compensating for the shortfall in H1. - Improvement in EBITDA expected in H2 FY '26 as 60% of sales ramp-up occurs, with gross contribution improving from 49.3% to 51%. - EBITDA for FY '25 was INR44 crores; H2 FY '26 target around INR30 crores, indicating a recovery trajectory. - FY '27 outlook is optimistic with expectations of 20%-25% revenue growth and EBITDA margins of around 14%-15%, contingent on successful EU-GMP certification and remediation. - Margin improvement driven by product mix normalization, operational efficiencies, and resumption of innovative product sales starting from Q1 or Q2 FY '27. - Capex largely completed with minor additional spends (~INR5 crores) for CAPA implementation, no significant borrowing increase expected. - Working capital to increase proportionately with turnover; gearing ratios expected to remain stable.

- The company has a robust order book with orders already in hand, providing confidence for achieving year-end targets similar to the previous year. - For innovative products like NIP and OTF, there was a shortfall in H1 due to audit-related prudence delaying order execution, but orders are moderating and expected to compensate in H2. - Orders that were delayed in H1 for some customers are expected to come in H2, aiming to reach prior run rates of around INR 15-16 crores per quarter for NIP and OTF products. - The business plan anticipates roughly 60% of annual business in H2, based on existing orders and expected government orders. - The company has built inventory and secured orders for the second half to compensate for the shortfall in H1. - Continued growth visibility exists due to marketing authorizations received, and new product commercialization timelines of 3-6 months post-approval.